title: Ubiquinol-10 supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome.
abstract: The aim of this study was to evaluate the benefit of oral ubiquinol-10 supplementation in CFS patients using an open-label study and a randomized, double-blinded, placebo-controlled (RCT) study. Twenty patients with CFS were randomly enrolled in an 8-week open-label oral ubiquinol-10 (150 mg ubiquinol-10/day) study. The patients and the attending physicians were not blinded to the supplementation. Forty-three patients with CFS were randomly assigned to receive either ubiquinol-10 (150 mg/day) or placebo every day for 12 weeks. The patients and the attending physicians were blinded to the supplementation, and a total of 31 patients (N = 17 in the ubiquinol group and 14 in the placebo group) completed the study. The beneficial effects of ubiquinol-10 were observed in the open-label study we conducted prior to the RCT. The RCT results suggest that supplementation with ubiquinol-10 for 12 weeks is effective for improving several CFS symptoms. © 2016 BioFactors, 42(4):431-440, 2016.
authors.affiliation: University of Kansai Welfare Sciences, 3-11-1 Asahigaoka, Kashiwara, Osaka, 582-0026, Japan.|RIKEN Center for Life Science Technologies, 6-7-3 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.|Department of Physiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abenoku, Osaka City, Osaka, 545-8585, Japan.
authors.forename: Sanae
authors.initials: S
authors.lastname: Fukuda
authors.affiliation: Yamaguchi University Graduate School of Medicine, 1-1-1 Minamiogushi, Ube City, Yamaguchi, 755-8505, Japan.
authors.forename: Junzo
authors.initials: J
authors.lastname: Nojima
authors.affiliation: Department of Medical Science on Fatigue, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abenoku, Osaka City, Osaka, 545-8585, Japan.
authors.forename: Osami
authors.initials: O
authors.lastname: Kajimoto
authors.affiliation: Department of Physiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abenoku, Osaka City, Osaka, 545-8585, Japan.|Department of Endocrinology, Metabolism and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abenoku, Osaka City, Osaka, 545-8585, Japan.
authors.forename: Kouzi
authors.initials: K
authors.lastname: Yamaguti
authors.affiliation: Department of Physiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abenoku, Osaka City, Osaka, 545-8585, Japan.|Department of Endocrinology, Metabolism and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abenoku, Osaka City, Osaka, 545-8585, Japan.
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Nakatomi
authors.affiliation: University of Kansai Welfare Sciences, 3-11-1 Asahigaoka, Kashiwara, Osaka, 582-0026, Japan.|Department of Physiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abenoku, Osaka City, Osaka, 545-8585, Japan.|Department of Endocrinology, Metabolism and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abenoku, Osaka City, Osaka, 545-8585, Japan.
authors.forename: Hirohiko
authors.initials: H
authors.lastname: Kuratsune
authors.affiliation: RIKEN Center for Life Science Technologies, 6-7-3 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.|Department of Physiology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abenoku, Osaka City, Osaka, 545-8585, Japan.
authors.forename: Yasuyoshi
authors.initials: Y
authors.lastname: Watanabe
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001341:Autonomic Nervous System / Q000187:drug effects; D015415:Biomarkers / Q000097:blood; D019587:Dietary Supplements; D004311:Double-Blind Method; D005221:Fatigue / Q000188:drug therapy; D015673:Fatigue Syndrome, Chronic / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D016896:Treatment Outcome; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D000975:Antioxidants; D015415:Biomarkers; D014451:Ubiquinone; C026663:ubiquinol-10
keywords: chronic fatigue syndrome; double-blind; placebo-controlled trial; randomized; ubiquinol-10